Whether the lactate transport carrier is a biomarker for type 2 diabetes?

Not Applicable

• Conditions: Type2 diabetes

• Registration Number: JPRN-UMIN000035924
• Lead Sponsor: Hokkaido University Hospital, Department of Pharmacy

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-02-18
• Study Completion: 2021-03-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 86

Inclusion Criteria

Not provided

Exclusion Criteria

(1) Patients diagnosed as type1 diabetes, or a pancreas-associated autoantibody such as glutamic acid decarboxylase antibody was positive. (2) Patients diagnosed as respiratory failure or serious liver failure. (3) Patients who were judged inappropriate as the subject by the research director.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Correlation between plasma lactate, alanine and known diabetes marker (fasting blood glucose, HbA1c, insulin secretion ability etc.).

Secondary Outcome Measures

Name	Time	Method
1. Correlation between plasma lactate, alanine and clinical information (age, sex, body weight, BMI, renal function, TG, LDL, HDL etc.). 2. Differences in the frequency of polymorphisms of diabetes-related genes in MCT 1, 4, 11 and the relationship between lactate and alanine and known diabetes markers.